With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.220641-87-2,N-Methyltetrahydro-2H-pyran-4-amine,as a common compound, the synthetic route is as follows.,220641-87-2
Step 3. 4-{ [(Furo[2,3-c]pyridine-2-carbonyl)-amino]-methyl}-benzenesulfonyl chloride (133 mg, 0.38 mmol) was added to a mixture of N-methyltetrahydro-2H-pyran-4- amine (92 mg, 0.76 mmol) and triethylamine (0.27 mL, 1.90 mmol) in DCM (1 mL). The reaction mixture was stirred at rt for 24 h and then concentrated to dryness under vacuum. The residue was purified by preparative HPLC (column: Gemini-NX, 3 x 10 cm, 10 um; detection: UV 254 nm; mobile phase A: H20 containing 0.1% NH4OH, mobile phase B: Acetonitrile; flow rate: 60 mL/min, gradient: 0-1 min 5% B, 1-10 min 5-50% B, 10-11 min 50% B, 11-11.2 min 50-95% B, 11.2-13 min 95% B, 13-13.2 min 95-5% B, 13.2-15 min. 5% B). Isolation and concentration of the appropriate fractions afforded the title compound as a white solid (34.6 mg, 21.2%). 1H NMR (400 MHz, DMSO-J6) delta 9.65 (t, J = 6.2 Hz, 1H), 9.07 (s, 1H), 8.49 (d, J = 5.0 Hz, 1H), 7.82 (dd, J = 15.2, 6.6 Hz, 3H), 7.67 (s, 1H), 7.55 (d, J = 8.1 Hz, 2H), 4.59 (d, J = 6.1 Hz, 2H), 3.95 (tt, J = 12.1, 4.3 Hz, 1H), 3.79 (dd, J = 11.5, 4.3 Hz, 2H), 3.29 (d, J = 11.7 Hz, 2H), 2.67 (s, 3H), 1.60 (qd, J = 12.2, 4.5 Hz, 2H), 1.27 – 1.13 (m, 2H). LC/MS (Method M, ESI): RT = 3.57 min, m/z = 430.2 [M + H]+.
As the paragraph descriping shows that 220641-87-2 is playing an increasingly important role.
Reference£º
Patent; GENENTECH, INC.; FORMA TM, LLC; BAIR, Kenneth, W.; BAUMEISTER, Timm, R.; BUCKMELTER, Alexandre, J.; CLODFELTER, Karl, H.; GUNZNER-TOSTE, Janet; HAN, Bingsong; LIN, Jian; REYNOLDS, Dominic, J.; SMITH, Chase, C.; WANG, Zhongguo; ZAK, Mark; ZHENG, Xiaozhang; ZHAO, Guiling; WO2013/130943; (2013); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics